Cargando…
Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review
Immune checkpoint inhibitors (ICIs) have substantially changed the treatment of a variety of malignant tumors. With the increasing of their usage, the unique immune-mediated toxicity profile of ICIs has become apparent. We report a case of esophageal squamous cell carcinoma in a patient who received...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761813/ https://www.ncbi.nlm.nih.gov/pubmed/35047395 http://dx.doi.org/10.3389/fonc.2021.778185 |
_version_ | 1784633615579086848 |
---|---|
author | Bai, Jing Li, Dan Yang, Peidan Xu, Kunyan Wang, Yingnan Li, Qian Liu, Jiang Du, Wenli Zhang, Fengbin Feng, Rui |
author_facet | Bai, Jing Li, Dan Yang, Peidan Xu, Kunyan Wang, Yingnan Li, Qian Liu, Jiang Du, Wenli Zhang, Fengbin Feng, Rui |
author_sort | Bai, Jing |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs) have substantially changed the treatment of a variety of malignant tumors. With the increasing of their usage, the unique immune-mediated toxicity profile of ICIs has become apparent. We report a case of esophageal squamous cell carcinoma in a patient who received anti-programmed cell death protein 1 (PD-1) (camrelizumab) therapy and the occurrence of sequential immune-related adverse events (irAEs). Although many irAEs have been reported, severe myositis caused by camrelizumab with simultaneous involvement of multiple organs, including the myocardium, respiratory muscles, and skeletal muscles, has rarely been described in literature. This 69-year-old male patient developed a grade 4 camrelizumab-induced adverse reaction according to the Common Terminology Criteria for Adverse Events (CTCAE) and was successfully treated with methylprednisolone and immunoglobulins. The early identification of irAEs, immediate discontinuation of immunotherapy, use of steroids and/or immunosuppressants, and adjuvant supportive treatment are critical to the clinical prognosis of patients. It should be aware that autoimmune complications can occur even when ICI treatment is ceased. |
format | Online Article Text |
id | pubmed-8761813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87618132022-01-18 Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review Bai, Jing Li, Dan Yang, Peidan Xu, Kunyan Wang, Yingnan Li, Qian Liu, Jiang Du, Wenli Zhang, Fengbin Feng, Rui Front Oncol Oncology Immune checkpoint inhibitors (ICIs) have substantially changed the treatment of a variety of malignant tumors. With the increasing of their usage, the unique immune-mediated toxicity profile of ICIs has become apparent. We report a case of esophageal squamous cell carcinoma in a patient who received anti-programmed cell death protein 1 (PD-1) (camrelizumab) therapy and the occurrence of sequential immune-related adverse events (irAEs). Although many irAEs have been reported, severe myositis caused by camrelizumab with simultaneous involvement of multiple organs, including the myocardium, respiratory muscles, and skeletal muscles, has rarely been described in literature. This 69-year-old male patient developed a grade 4 camrelizumab-induced adverse reaction according to the Common Terminology Criteria for Adverse Events (CTCAE) and was successfully treated with methylprednisolone and immunoglobulins. The early identification of irAEs, immediate discontinuation of immunotherapy, use of steroids and/or immunosuppressants, and adjuvant supportive treatment are critical to the clinical prognosis of patients. It should be aware that autoimmune complications can occur even when ICI treatment is ceased. Frontiers Media S.A. 2022-01-03 /pmc/articles/PMC8761813/ /pubmed/35047395 http://dx.doi.org/10.3389/fonc.2021.778185 Text en Copyright © 2022 Bai, Li, Yang, Xu, Wang, Li, Liu, Du, Zhang and Feng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Bai, Jing Li, Dan Yang, Peidan Xu, Kunyan Wang, Yingnan Li, Qian Liu, Jiang Du, Wenli Zhang, Fengbin Feng, Rui Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review |
title | Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review |
title_full | Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review |
title_fullStr | Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review |
title_full_unstemmed | Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review |
title_short | Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review |
title_sort | camrelizumab-related myocarditis and myositis with myasthenia gravis: a case report and literature review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761813/ https://www.ncbi.nlm.nih.gov/pubmed/35047395 http://dx.doi.org/10.3389/fonc.2021.778185 |
work_keys_str_mv | AT baijing camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview AT lidan camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview AT yangpeidan camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview AT xukunyan camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview AT wangyingnan camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview AT liqian camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview AT liujiang camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview AT duwenli camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview AT zhangfengbin camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview AT fengrui camrelizumabrelatedmyocarditisandmyositiswithmyastheniagravisacasereportandliteraturereview |